Corporate Magazine 2012 - Boehringer Ingelheim

More documents

Recommendations

Info

product portfolioconsumer health careIndications Brand names Active ingredients• Acute and chronic bronchopulmonarydiseasesmucosolvan®mucosan®surbronc®lasolvan®mucopect®ambroxolSecretolytic therapy in acute and chronicbronchopulmonary diseases associatedwith abnormal mucus secretion and impairedmucus transport.• Acute and chronic bronchopulmonarydiseasesbisolvon® bromhexine Secretolytic therapy in acute and chronicbronchopulmonary diseases associatedwith abnormal mucus secretion and impairedmucus transport.• Irritable coughsilomat® dmpbisoltussin®bisolvon® drybisolsek®bisolvon® antitusivodextrometorphanSymptomatic treatment of irritable, nonproductivecough.Indications Brand names Active ingredients• Sore throatmucoangin®lysopadol®lysopain® dolisodinemint®zerinol® golaambroxolPain relief in acute sore throat.Cough and cold / Sore throat81
Gastrointestinal diseasesIn our gastrointestinal portfolio, we offer several brandssuch as dulcolax®, surulac®, laxoberal®, guttalax®,buscopan®, as well as the heartburn brands zantac®and buscopan® antiacido and gastol®.Constipation is a common problem. dulcolax® is theleading over-the-counter (OTC) laxative remedy forconstipation relief worldwide.Within the dulcolax® franchise, Boehringer Ingelheimmarkets a range of products for the treatment, regulationand prevention of intestinal irregularity and disruption.The primary ailment within this area is constipation,for which dulcolax® tablets are today the mainmethod of treatment.dulcolax® tablets have a special enteric “comfortcoating” which ensures that the active ingredient indulcolax® tablets, bisacodyl, is taken to where it needsto act – the colon. Here, in the colon, the colonic juicesactivate the key ingredient, which then relieves constipation.It stimulates the natural movement of the bowelsto provide gentle, predictable relief within 6 –12 hours.One to two tablets taken before going to bed will stillprovide relief the next morning.dulcolax® is specifically formulated to provide effective,predictable relief for constipation. dulcolax® offersa reliable range of products.Abdominal cramping, pain and discomfort are commonailments. Approximately one in four persons worldwidesuffers on a regular basis.buscopan® is an antispasmodic product with the activeingredient hyoscine butylbromide. The product is basicallya natural substance extracted from Duboisia plant speciesas scopolamine (hyoscine) and chemically modifiedto the quaternary ammonium compound hyoscine butylbromide.As an antispasmodic product, buscopan® actsdirectly on the site of abdominal pain by relaxing thesmooth muscles of the gastrointestinal, biliary, urinaryand genital tracts.This means buscopan® relieves abdominal pain by directlytreating its main cause – abdominal cramp orspasm.Several buscopan® line extensions are available today –the mono-variant and different combinations withanalgesics (paracetamol, ibuprofen and metamizol/dipyrone)– and different formulations (tablets, drops, suppositories,syrup and solutions for intravenous injection).The umbrella brand buscopan® also offers buscofem®for mentstrul pain relief, buscopan® antiacido andbuscopan® reflusso for heartburn relief.Other products within the dulcolax® range includedulcoease® (stool softener), dulcoenema®,dulcobalance® and dulcogas®.surulac® is the constipation brand in Japan, whereconsumers are offered surulac® as a laxative tablet.laxoberal® and guttalax® are the brands offeringconsumers constipation relief with a unique and flexibledosage format – namely drops.82Boehringer Ingelheim annual report 2012
Page 1 and 2:
Value through InnovationCorporate M
Page 3 and 4:
our businesses66 [ prescription med
Page 7:
value through innovationperspective
Page 10 and 11:
56° 40' 59" N, 5° 6' 14" Wglencoe
Page 12 and 13:
56° 40' 59" N, 5° 6' 14" Wglencoe
Page 14 and 15:
PERSPECTIVES FORSOCIETYIn all our a
Page 16 and 17:
50 NATIONSPeople from around 50 nat
Page 18 and 19:
“RLDP journey: a great learning o
Page 20 and 21:
SHONA MCDONALD, SHONAQUIP[ south af
Page 22 and 23:
SEHNAZ LAYIKEL, RUSIHAK[ turkey ]he
Page 24 and 25:
Thalita Guimaraes joins the “Boeh
Page 26 and 27:
When handling chemicals, employees
Page 28 and 29:
11 With its own wastewater treatmen
Page 30 and 31:
21 Dr Carolyn R. Bertozzi received
Page 32 and 33:
PERSPECTIVES FOR THE SOCIETYOF TOMO
Page 34 and 35:
The opening ceremony of IMB:Interac
Page 36 and 37:
CIRCUIT MECHANICS OF EMOTIONSUnders
Page 38 and 39:
BIBERACH UNIVERSITY OF APPLIEDSCIEN
Page 40 and 41:
22° 41' 0" S, 14° 32' 0" Eswakopm
Page 42 and 43:
22° 41' 0" S, 14° 32' 0" Eswakopm
Page 44 and 45:
PERSPECTIVES FORMEDICAL INNOVATIONB
Page 46 and 47:
RESEARCH PARTNERSHIPS WITHACADEMIA
Page 48 and 49:
collaborate innovate accelerateTRAN
Page 50 and 51:
GLORIA-AF®Registry programme for p
Page 52 and 53:
BOEHRINGER INGELHEIM ONCOLOGY FRANC
Page 54 and 55:
AFATINIB BLOCKS THE ERBB RECEPTORSE
Page 56 and 57:
HEPTATIS C VIRUS (HCV) INFECTIONHCV
Page 58 and 59:
1viral entryrnareleasernatranslated
Page 60 and 61:
12THE MAIN COMPLICATIONS OF DIABETE
Page 62 and 63:
ASTHMAAsthma is a chronic disease c
Page 64 and 65:
THERAPEUTIC AREA (TA) REVIEW CORE T
Page 66 and 67:
6° 59' 15" N, 125° 16' 15" Eapo,
Page 68 and 69:
icardo f. solitariadistrict manager
Page 70 and 71:
PERSPECTIVES FORBETTER HEALTHBoehri
Page 72 and 73:
“My photo shows Frau Röhrigfrom
Page 74 and 75:
OUR CARDIOVASCULAR PORTFOLIOaggreno
Page 76 and 77:
HOW ATRIAL FIBRILLATION (AF)LEADS T
Page 78 and 79:
FINDING THE RIGHT MOLECULE“Findin
Page 80 and 81:
PATIENTS AT CARDIOVASCULAR RISKMost
Page 82 and 83:
TRAJENTA® / TRADJENTA®trajenta®
Page 84 and 85:
WORLD DIABETES DAYWorld Diabetes Da
Page 86 and 87:
SPIRIVA®: 10 YEARS AND MORE OF CLI
Page 88 and 89:
BEHAVIOUR CHANGE INTYPE 2 DIABETEST
Page 90 and 91:
Rapid progress in global healthcare
Page 92 and 93:
KEY GOALS OF GLOBAL BUSINESS SERVIC
Page 94 and 95:
“The perspectives that open upune
Page 96 and 97:
OUR GLOBAL SWITCH TEAMThe Switch un
Page 98 and 99:
“For me, the photo shows thatthe
Page 100 and 101:
2 Disposable single use bioreactorw
Page 102 and 103:
“The hard-working beessuccessfull
Page 104 and 105:
“There are many things and experi
Page 106 and 107:
OUR GLOBAL SCIENTIFIC NET WORKIN AN
Page 108 and 109:
2 31 Scientists in Hannover working
Page 110 and 111:
“Living and working on a differen
Page 112 and 113:
1 Phoenix, the first captive-bredOr
Page 114 and 115:
55° 21' 0" N, 131° 40' 24" Wketch
Page 116 and 117:
scott zhangstrategic effectiveness
Page 118 and 119:
PERSPECTIVES FORQUALITY IN OPERATIO
Page 120 and 121:
With the quality risk management sy
Page 122 and 123:
In order to ensure patient safety,
Page 124 and 125:
37° 34' 48" N, 14° 16' 34" Esicil
Page 126 and 127:
37° 34' 48" N, 14° 16' 34" Esicil
Page 128 and 129:
PERSPECTIVES FORESTABLISHED MARKETS
Page 130 and 131:
Spain is one of the countries struc
Page 132 and 133:
21 View of Athens.2 Production site
Page 134 and 135:
1 View of San Francisco, the leadin
Page 136 and 137:
211 View of Tokyo with Japan’s hi
Page 138 and 139:
IF YOU HAVE ANY QUERIES OR COMMENTS
Page 140 and 141:
Value through InnovationBusiness Ye
Page 142 and 143:
product portfolio70 [ branded presc
Page 144 and 145:
usiness year 2012our companyOUR COM
Page 146 and 147:
usiness year 2012the shareholders
Page 148 and 149:
usiness year 2012the shareholders
Page 150 and 151:
usiness year 2012 key aspects 2012S
Page 152 and 153:
usiness year 2012 key aspects 2012F
Page 154 and 155:
usiness year 2012 key aspects 2012B
Page 156 and 157:
usiness year 2012corporate bodiesCO
Page 158 and 159:
usiness year 2012group management r
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171: usiness year 2012group management r
Page 178 and 179: usiness year 2012consolidated finan
Page 206 and 207: usiness year 2012auditor’s report
Page 208 and 209: product portfolioa selection2012PRO
Page 210 and 211: product portfoliobranded prescripti
Page 222 and 223: product portfolioconsumer health ca
Page 228 and 229: product portfolioanimal healthIndic
Page 236 and 237: usiness year 2012financial data2006
Page 238: www.boehringer-ingelheim.comannualr
show all

Corporate Magazine 2012 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?